| |
| |
|
| Insider
Information: |
Graham Dawn |
| Relationship: |
Director |
| City: |
San Francisco |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
7 |
|
| Direct
Shares |
119,017 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$1,640,116 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
119,017 |
|
|
| Total
Value |
$1,640,116 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
3
|
5
|
|
Stock
price went up :
|
0
|
3
|
| Stock
price went down : |
3
|
2
|
| |
|
|
|
Gain/Loss Ratio : |
-3.0
|
1.5
|
| Percentage
Gain/Loss : |
 -56.0%
|
 67.9%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Medivation Inc |
MDVN |
Director |
2016-09-28 |
0 |
2013-04-22 |
0 |
Premium* |
|
|
PTC Therapeutics, Inc. |
PTCT |
|
2022-06-09 |
29,017 |
2017-05-23 |
0 |
Premium* |
|
|
Xenon Pharmaceuticals Inc. |
XENE |
|
2023-08-24 |
25,000 |
2017-08-14 |
0 |
Premium* |
|
|
Endocyte Inc |
ECYT |
Director |
2018-12-21 |
0 |
2018-05-03 |
0 |
Premium* |
|
|
Global Blood Therapeutics, Inc. |
GBT |
Director |
2022-10-05 |
0 |
2020-06-17 |
0 |
Premium* |
|
|
Adverum Biotechnologies, Inc |
AAVL |
Director |
2022-05-16 |
50,000 |
2021-03-31 |
0 |
Premium* |
|
|
Acelyrin, Inc. |
SLRN |
Director |
2023-05-09 |
15,000 |
2023-05-09 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| XENE |
Xenon Pharmaceuticals Inc... |
|
– • – |
2023-08-24 |
4 |
S |
$38.70 |
$967,500 |
D/D |
(25,000) |
25,000 |
0 |
- |
|
| SLRN |
Acelyrin, Inc. |
Director |
– • – |
2023-05-09 |
4 |
B |
$18.00 |
$270,000 |
D/D |
15,000 |
15,000 |
2.39 |
% |
|
| GBT |
Global Blood Therapeutics... |
Director |
– • – |
2022-10-05 |
4 |
D |
$0.00 |
$0 |
D/D |
(5,376) |
0 |
0 |
- |
|
| GBT |
Global Blood Therapeutics... |
Director |
– • – |
2022-06-21 |
4 |
AS |
$27.24 |
$51,983 |
D/D |
(1,908) |
5,376 |
0 |
% |
|
| GBT |
Global Blood Therapeutics... |
Director |
– • – |
2022-06-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,600 |
7,284 |
0 |
- |
|
| PTCT |
PTC Therapeutics, Inc. |
|
– • – |
2022-06-09 |
4 |
S |
$27.20 |
$20,074 |
D/D |
(738) |
29,017 |
0 |
% |
|
| AAVL |
Adverum Biotechnologies, ... |
Director |
– • – |
2022-05-16 |
4 |
B |
$0.85 |
$25,578 |
D/D |
30,000 |
50,000 |
2.39 |
% |
|
| PTCT |
PTC Therapeutics, Inc. |
Director |
– • – |
2022-01-07 |
4 |
S |
$38.53 |
$19,648 |
D/D |
(510) |
26,555 |
0 |
% |
|
| PTCT |
PTC Therapeutics, Inc. |
Director |
– • – |
2022-01-07 |
4 |
A |
$0.00 |
$0 |
D/D |
3,200 |
29,755 |
0 |
- |
|
| GBT |
Global Blood Therapeutics... |
Director |
– • – |
2021-06-18 |
4 |
AS |
$36.54 |
$58,793 |
D/D |
(1,609) |
3,684 |
0 |
% |
|
| GBT |
Global Blood Therapeutics... |
Director |
– • – |
2021-06-17 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,037 |
5,293 |
0 |
- |
|
| PTCT |
PTC Therapeutics, Inc. |
Director |
– • – |
2021-06-09 |
4 |
S |
$41.89 |
$15,288 |
D/D |
(365) |
27,065 |
0 |
% |
|
| AAVL |
Adverum Biotechnologies, ... |
Director |
– • – |
2021-03-31 |
4 |
B |
$10.02 |
$200,338 |
D/D |
20,000 |
20,000 |
2.39 |
% |
|
| PTCT |
PTC Therapeutics, Inc. |
Director |
– • – |
2021-02-01 |
4 |
S |
$56.96 |
$28,820 |
D/D |
(506) |
27,430 |
0 |
% |
|
| PTCT |
PTC Therapeutics, Inc. |
Director |
– • – |
2021-01-06 |
4 |
A |
$0.00 |
$0 |
D/D |
1,650 |
27,936 |
0 |
- |
|
| GBT |
Global Blood Therapeutics... |
Director |
– • – |
2020-06-19 |
4 |
AS |
$63.69 |
$162,663 |
D/D |
(2,544) |
2,256 |
0 |
% |
|
| GBT |
Global Blood Therapeutics... |
Director |
– • – |
2020-06-17 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,800 |
4,800 |
0 |
- |
|
| PTCT |
PTC Therapeutics, Inc. |
Director |
– • – |
2020-06-11 |
4 |
S |
$48.36 |
$17,603 |
D/D |
(364) |
26,286 |
0 |
% |
|
| PTCT |
PTC Therapeutics, Inc. |
Director |
– • – |
2020-01-29 |
4 |
A |
$0.00 |
$0 |
D/D |
1,650 |
26,650 |
0 |
- |
|
| ECYT |
Endocyte Inc |
Director |
– • – |
2018-12-21 |
4 |
D |
$24.00 |
$169,200 |
D/D |
(7,050) |
0 |
0 |
- |
|
| ECYT |
Endocyte Inc |
Director |
– • – |
2018-05-03 |
4 |
A |
$0.00 |
$0 |
D/D |
7,050 |
7,050 |
0 |
- |
|
| XENE |
Xenon Pharmaceuticals Inc... |
Director |
– • – |
2017-08-14 |
4 |
B |
$2.82 |
$140,770 |
D/D |
50,000 |
50,000 |
2.39 |
- |
|
| PTCT |
PTC Therapeutics, Inc. |
Director |
– • – |
2017-05-23 |
4 |
B |
$13.49 |
$337,230 |
D/D |
25,000 |
25,000 |
2.39 |
- |
|
| MDVN |
Medivation Inc |
Director |
– • – |
2016-09-28 |
4 |
D |
$0.00 |
$0 |
D/D |
(21,206) |
0 |
0 |
- |
|
| MDVN |
Medivation Inc |
Director |
– • – |
2016-06-22 |
4 |
A |
$0.00 |
$0 |
D/D |
2,972 |
21,206 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
